Ensartinib before surgery for ALK-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a pill called ensartinib, given before surgery to people with ALK-positive lung cancer. The goal is to see if it helps shrink the tumor and improve the chance of successful surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have a type of lung cancer called adenocarcinoma that has the ALK marker.
- Your cancer is at a stage that can be operated on (Stage IIA to IIIB).
- You have not had any previous treatment for this lung cancer, like chemotherapy or radiation.
- Your cancer has not spread to the brain, based on scans.
- You are generally in good health, with normal blood counts and organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests the drug ensartinib, given before surgery, for people with ALK-positive lung cancer. Taking ensartinib first might shrink the tumor and make surgery more effective.
This study tests whether combining an EGFR-targeted pill with chemotherapy before surgery can shrink or control early-stage non-small cell lung cancer that has an EGFR mutation. It aims to improve outcomes for patients whose tumors can be removed surgically.
This study tests whether giving a new targeted pill (iruplaltinib) along with chemotherapy before surgery can help shrink tumors and improve outcomes for people with ALK-positive lung cancer. Participation involves taking study drugs, having tests, and then undergoing surgery.
This trial tests the drug ensartinib to shrink lung cancer before surgery. It is for people with ALK-positive lung cancer that can be surgically removed.
This trial tests whether taking a pill called ensartinib after surgery can help prevent early stage lung cancer from coming back. It is for people whose tumors have a specific gene change called ALK and who have high-risk features.
This trial tests whether taking the targeted therapy Ensartinib (which blocks ALK) along with standard chemotherapy before surgery can help shrink ALK-positive lung cancer and improve outcomes. It is for people who have not yet had treatment and whose cancer is at a stage that can be removed with surgery.
Hear when a new MPR trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.